U.S. markets close in 23 minutes

Vycor Medical, Inc. (VYCO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.16980.0000 (0.00%)
As of 12:11PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1698
Open0.1698
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1698 - 0.1698
52 Week Range0.0250 - 0.4780
Volume100
Avg. Volume17,965
Market Cap4.737M
Beta (5Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0440
Earnings DateMar 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement

    Vycor Medical, Inc. (“Vycor”) (OTCBB—VYCO) today announced that its wholly owned subsidiary, NovaVision, Inc. (“NovaVision”), has signed an agreement in principle to enter into an exclusive licensing agreement with HelferApp GmbH (“HelferApp”). Under the terms of the agreement HelferApp will have the exclusive rights for NovaVision’s diagnostic products and therapies provided direct to the patient and to medical professionals in Germany, Austria and Switzerland. The combination of the NovaVision therapies will allow HelferApp to create an unrivalled portfolio of scientifically supported therapies addressing the visual rehabilitation market in the territories.